Oregon Health & Science University (OHSU) is conducting a Phase I clinical trial of StemCells, Inc.'s proprietary human neural stem cell product (HuCNS-SC (TM)) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis
(NCL), two forms of a group of disorders often referred to as Batten disease. NCL is a rare and fatal neurodegenerative
genetic condition affecting infants and children.
